Symptoms and diagnosis
Home
Usage examples
Diseases
Therapies
Medicinal plants
Frequent searches
Medical search
Health topics
Healthy weight
Medical dictionary
Health sites
Questions and answers
Advertisement
Oncothyreon (ONTY) Price Target Lowered to $3 at Wedbush
"While we are removing tecemotide from our valuation, we are adding the opportunity for ONTY's newly acquired protocell technology in primary hyperoxaluria type 1 (PH-1). Protocell technology, gained as part of the recent Alpine Biosciences acquisition ...
StreetInsider.com (subscription) - Tue, 19 Aug 2014 05:33

Dicerna Provides Operational Update and Reports Second Quarter 2014 ...
DCR-PH1 is a therapeutic candidate for Primary Hyperoxaluria 1 (PH1), a rare, inherited autosomal recessive disorder of metabolism in the liver that usually results in life-threatening damage to the kidneys. In the genetic mouse model of PH1, Dicerna ...
Business Wire (press release) - Thu, 07 Aug 2014 12:52

Dicerna On Track with Drug Candidates, Initial Cancer Rx Data Expected in '15
NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this month confirmed previous guidance on its two drug candidates, the solid tumor therapy DCR-MYC and the primary hyperoxaluria 1 (PH1) treatment DCR-PH1, stating that both agents remain on track ...
GenomeWeb - Thu, 21 Aug 2014 07:30


1  

Last update: September 2014
Statistics


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014
Statistics